The recently announced clinical trials utilizing gene therapy for the treatment of heart failure, marks the culmination of more than 20 years of research funded by the British Heart Foundation (BHF) at Imperial College London and Royal Brompton Hospital (London, UK), which have identified SERCA2a as an important factor affecting how well heart muscle cells can contract in people with heart failure.
展开▼
